RING PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
RING PHARMA
Largest movements
- Receivables within one year -€482,784
down €482,784 (-92.5%), from €522,000 to €39,216
of which Other amounts receivable: -€520,434
- Cash -€124,762
down €124,762 (-64.6%), from €193,052 to €68,291
mainly Debts after one year (-€463,574) and Net result for the year (-€104,944)
- Tangible fixed assets +€40,988
up €40,988 (+7.4%), from €551,917 to €592,905
of which Plant, machinery and equipment: +€57,808
- Debts after one year -€463,574
down €463,574 (-23.0%), from €2.0m to €1.6m
- Profit (loss) carried forward -€104,944
down €104,944 (-41.4%), from -€253,658 to -€358,602
- Financial income -€92,420
down €92,420 (-87.3%), from €105,920 to €13,500
- Gross operating margin -€15,502
down €15,502 (-40.9%), from €37,930 to €22,429
- Other operating charges +€4,421
up €4,421 (+95.1%), from €4,651 to €9,072
- Financial charges -€2,363
down €2,363 (-2.0%), from €117,344 to €114,981
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,137,556 | €1,570,999 | -€566,557 | -26.5% |
| Fixed assets | 21/28 | €1,422,504 | €1,463,492 | +€40,988 | +2.9% |
| Tangible fixed assets | 22/27 | €551,917 | €592,905 | +€40,988 | +7.4% |
| Land and buildings | 22 | €513,890 | €497,071 | -€16,820 | -3.3% |
| Plant, machinery and equipment | 23 | - | €57,808 | +€57,808 | |
| Furniture and vehicles | 24 | €38,026 | €38,026 | = | 0.0% |
| Financial fixed assets | 28 | €870,587 | €870,587 | = | 0.0% |
| Current assets | 29/58 | €715,052 | €107,506 | -€607,546 | -85.0% |
| Amounts receivable within one year | 40/41 | €522,000 | €39,216 | -€482,784 | -92.5% |
| Trade receivables | 40 | - | €37,650 | +€37,650 | |
| Other amounts receivable | 41 | €522,000 | €1,566 | -€520,434 | -99.7% |
| Cash at bank and in hand | 54/58 | €193,052 | €68,291 | -€124,762 | -64.6% |
| Total equity and liabilities | 10/49 | €2,137,556 | €1,570,999 | -€566,557 | -26.5% |
| Equity | 10/15 | €102,532 | -€2,412 | -€104,944 | |
| Contributions | 10/11 | €200,000 | €200,000 | = | 0.0% |
| Capital | 10 | €200,000 | €200,000 | = | 0.0% |
| Issued capital | 100 | €250,000 | €250,000 | = | 0.0% |
| Uncalled capital | 101 | €50,000 | €50,000 | = | 0.0% |
| Reserves | 13 | €156,190 | €156,190 | = | 0.0% |
| Non-distributable reserves | 130/1 | €25,000 | €25,000 | = | 0.0% |
| Legal reserve | 130 | €25,000 | €25,000 | = | 0.0% |
| Distributable reserves | 133 | €131,190 | €131,190 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€253,658 | -€358,602 | -€104,944 | -41.4% |
| Amounts payable | 17/49 | €2,035,024 | €1,573,410 | -€461,613 | -22.7% |
| Amounts payable after more than one year | 17 | €2,017,790 | €1,554,217 | -€463,574 | -23.0% |
| Financial debts | 170/4 | €2,017,790 | €1,554,217 | -€463,574 | -23.0% |
| Amounts payable within one year | 42/48 | €17,233 | €19,194 | +€1,960 | +11.4% |
| Trade debts | 44 | €3,690 | €475 | -€3,215 | -87.1% |
| Suppliers | 440/4 | €3,690 | €475 | -€3,215 | -87.1% |
| Taxes, remuneration and social security | 45 | €13,177 | - | -€13,177 | |
| Taxes | 450/3 | €13,177 | - | -€13,177 | |
| Other amounts payable | 47/48 | €367 | €18,719 | +€18,352 | +5007.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €16,820 | €16,820 | = | 0.0% |
| Other operating charges | 640/8 | €4,651 | €9,072 | +€4,421 | +95.1% |
| Gross operating margin | 9900 | €37,930 | €22,429 | -€15,502 | -40.9% |
| Operating profit (loss) | 9901 | €16,460 | -€3,463 | -€19,923 | |
| Financial income | 75/76B | €105,920 | €13,500 | -€92,420 | -87.3% |
| Recurring financial income | 75 | €105,920 | €13,500 | -€92,420 | -87.3% |
| Financial charges | 65/66B | €117,344 | €114,981 | -€2,363 | -2.0% |
| Recurring financial charges | 65 | €117,344 | €114,981 | -€2,363 | -2.0% |
| Profit (loss) for the period before taxes | 9903 | €5,037 | -€104,944 | -€109,981 | |
| Profit (loss) for the period | 9904 | €5,037 | -€104,944 | -€109,981 | |
| Profit (loss) for the period to be appropriated | 9905 | €5,037 | -€104,944 | -€109,981 |
Source: filed annual accounts (NBB), fiscal years ended 30 September 2024 and 30 September 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.